Investor Presentaiton
CA9 indication expansion
New understanding leads to potential for applications beyond kidney cancer
•
A transmembrane protein and a
tumor-associated carbonic anhydrase
isoenzyme
Over-expressed in mutated ccRCC
and many hypoxic solid tumors, with
low expression in most normal tissue
High expression in tumours including
bladder or urothelial, breast, brain,
cervix, colon, esophagus, head and
neck, lung, ovarian, pancreatic and
vulval cancers
Imaging is being used to "indication
scout" for future therapy applications,
highlight the value of a "theranostic"
approach
Potential Indication
Status
Bladder or Urothelial Cancer
Commenced
Triple Negative Breast Cancer
Commenced
Lung Cancer
Planned
Ovarian Cancer
Planned
Colorectal Cancer
Planned
For personal use only
Telix Pharmaceuticals Limited (ASX: TLX)
Head and Neck Cancer
Planned
Pancreatic Cancer
Planned
44
TELIX
PHARMACEUTICALSView entire presentation